Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmunovantIMVT -1.34%29 3-Year Book Growth Rate is 14.60% as of Jun. 2026, which is at its 10-year median of 14.60. GuruFocus rates IMVT with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 1,131 Biotechnology companies, Immunovant ranks better than 81.34% on this metric.
During the past 12 months, Immunovant's average Book Value per Share Growth Rate was 0.50% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 14.60% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 2.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 8 years, the highest 3-Year average Book Value per Share Growth Rate of Immunovant was 1163.40% per year. The lowest was 1.00% per year. And the median was 14.60% per year.
Immunovant (NAS:IMVT) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Immunovant 3-Year Book Growth Rate Related Terms
IMVT vs PCVX, TGTX, PTGX: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Immunovant's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovant 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunovant's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Immunovant's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 14.60% mean?
Immunovant (IMVT) has a 3-Year Book Growth Rate of 14.60% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Immunovant and its competitors. This is near median its historical median of 14.60. Over the past decade, Immunovant's 3-Year Book Growth Rate has ranged from 1.00 to 1,163.40. According to the industry distribution chart, Immunovant ranks #211 out of 1131 companies in the Biotechnology industry, placing it in the top 18.7%.
Is Immunovant's 3-Year Book Growth Rate too high?
Immunovant's current 3-Year Book Growth Rate of 14.60% is near median its 10-year median of 14.60. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 1,163.40. Based on the distribution chart, Immunovant ranks #211 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immunovant has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Immunovant's 3-Year Book Growth Rate compare to PCVX and TGTX?
According to the Biotechnology industry distribution chart, Immunovant ranks #211 out of 1131 companies for 3-Year Book Growth Rate. This places Immunovant in the top 19% of its industry — outperforming the majority of peers. Historically, Immunovant's own 3-Year Book Growth Rate has ranged from 1.00 to 1,163.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Immunovant and its competitors. Immunovant's current 3-Year Book Growth Rate is 14.60%, which is near median its own 10-year median of 14.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovant stock overvalued right now?
Immunovant (IMVT) has a current 3-Year Book Growth Rate of 14.60%. The current 3-Year Book Growth Rate is 14.60%, which is near median its 10-year median of 14.60. Immunovant's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Immunovant (IMVT), the current 3-Year Book Growth Rate is 14.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
29GF Score
Get the complete analysis for IMVT
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMVT has been successfully added to your 
